Icon

TEMODAR (nda021029)- (5MG,20MG,100MG,140MG,180MG,250MG)

TEMOZOLOMIDE MERCK SHARP DOHME
5MG,20MG,100MG,140MG,180MG,250MG
Yes No
2014-Feb-11 Expired
2012-Mar-15 None
None No
TEMODAR is an alkylating drug indicated for the treatment of adult patients with: • Newly diagnosed glioblastoma concomitantly with radiotherapy and then as maintenance treatment. • Refractory anaplastic astrocytoma who have experienced disease progression on a drug regimen containing nitrosourea and procarbazine.
12 0 10
Total Other Developers 1
Drugs with Suitability No
5MG ** ** - - -
20MG ** ** - - 7
100MG ** ** - - 6
140MG ** ** - - 7
180MG ** ** - - -
250MG ** ** - - -
NDA Sales Available Total Generic Sales Available
No 5
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ******** ******* *********** *********** *** ****** *** ******, ********, ******** *** ***, ****** (***) ***
****** ******** ********** *********** *** *** *********** ***-********** ****, ****-*****, ******** ******** ******* **, **** *****, *******, ****** (***) ***
****** ****** ******** ***** *************** ******* *********** **** **. ***/***-****** / **** **.***/****-*********** , *******-***** ******* , ****** -******, ******, *********, ******* ******, ***** (***) ***
****** ****** ******** ***** *************** ******* *********** **** **. * ** **, *******, **** ******* ******, *******-***** *******, **. *-*, ****** ******, *********, ******* ******, ***** (***) ***
****** *** ***** *** ************** ********** ******* *********** *****-****** *******, *****, ******* ******, ***** (***) ***
****** ****** ****** ****** *************** ** *** ****, *** *********** ** ********** **, **********, *** **** (**) *****-****, ****** ****** (***) ***
****** ***** *** ********* *.*.* *********** *** ***** ******* **, ********, ****** *****, ***** (***) ***
****** ****** ***** ****** ************ ******* *********** ****-*, **. **. ***, *** & ***, ******* *******, ********* ******, *******-**********, ********* ******, ***** (***) ***
****** ****** ***** ****** ************ ******* *********** ****-***, **** **: *, ** ** **, ***, ** ** **, ****, *****, ***, ************ *******, ********** ******, **********, ********* ******, ***** (***) ***
****** ****** ***** ************** **., ***. ****** ***** *********** **. ** ********* *** **., ******* *******, ****** ****,****** ******, - *****, ****** (***) ***
****** ***** ****** ***** ************ ******* *********** **** **. *-*/*&* *******, (******* ******** ****) ******, ******* ***** *.*. **. **, ***-******, ****-*********, *********, ******* ******, ***** (***) ***
****** **** ******* ** **** ******* ****** ******* - ********* * ****** ****** ****** *********** ********* ******** ****** ***, **:** ******** ********* ***** *******, *******, ********, *****, ****** (***) ***
****** ****** **** *** * ****** **** ******* *********** **** *, **. **.: ***, ***, *** & ***, ***** *********** ***, ********* *******, ************, ********* ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.